Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 3

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 3
---
plAI. As a result of such termination, OmnigenicsAI will not acquire MultiplAI, their business will not be combined pursuant to the Business Combination Agreement, and all rights and obligations of MultiplAI under the Business Combination Agreement ceased and terminated, subject to certain exceptions. Prior to the Heritas Contribution (as defined herein), the Company has substantially conducted its business operations through Heritas SAU (“Heritas Argentina”). For more information, please refer to “ OmnigenicsAI Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The transactions contemplated by the Business Combination Agreement are referred to as the “Business Combination” and the closing of the Business Combination as the “Closing.” If the Business Combination is consummated, shareholders and warrant holders of APx (including through units previously issued by APx) will become shareholders and warrant holders of the Company, other than those holders of the Public Shares (as defined below) who elect to redeem their Public Shares. The other shareholders of the Company will include investors in the Company as of immediately prior to the Closing. This proxy statement/prospectus describes these matters and other important matters. This proxy statement/prospectus, which forms part of a registration statement on Form F -4filed with the U.S. Securities and Exchange Commission (the “SEC”) by the Company serves as: •A notice of meeting and proxy statement of APx under Section 14(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), for the extraordinary general meeting (the “Special Meeting”) of shareholders of APx to be held on , 2025, where APx shareholders will consider and vote on proposals (the “Proposals”) relating to the Business Combination and also the possible adjournment of the Special Meeting; and •A prospectus of the Company under Section 5 of the Securities Act of 1933, as amended (the “Securities Act”) relating to the securities of the Company to be issued in the Business Combination. The Proposals may be briefly summarized as follows: (1) Proposal No. 1 — The Business Combination Proposal— to consider and vote upon a proposal to approve by ordinary resolution the Business Combination Agreement, dated as of March 25, 2024 (as the same has been or may be amended, modified, supplemented or waived from time to time, the “Business Combination Agreement”), by and among APx, the Company, and Merger Sub, pursuant to which, among other things, Merger Sub will merge